BioCentury | Jun 17, 2013

Externalizing Astellas

With a stocked late-stage pipeline, Astellas Pharma Inc. has decided to restructure its R&D and give more attention to finding early stage programs by looking outside. The Japanese pharma will eliminate much of its bricks-and-mortar...
BC Week In Review | Sep 6, 2010
Clinical News

AGS-16M8F: Phase I started

Astellas' Agensys Inc. subsidiary began an open-label, dose-escalation, U.S. Phase I trial to evaluate AGS-16M8F in about 50 patients. AGS-16M8F uses antibody-drug conjugate technology from Seattle Genetics Inc. (NASDAQ:SGEN, Bothell, Wash.), which received an undisclosed...
Items per page:
1 - 2 of 2